Rhythm Pharmaceuticals (RYTM) Reports In-Line Q3 EPS

Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q3 EPS of ($0.76), in-line with the analyst estimate of ($0.76). Revenue for the quarter came in at $22.5 million versus the consensus estimate of $22.17 million.

For earnings history and earnings-related data on Rhythm Pharmaceuticals (RYTM) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Berenberg Starts Brooks Macdonald Group PLC (BRK:LN) at Buy
• RBC Capital Downgrades Bucher Industries AG (BUCN:SW) (BCHHF) to Sector Perform